Pain Drug Development Becomes Personalized
This article was originally published in RPM Report
Executive Summary
Advances in pain neurobiology point to the promise of more specific drugs with fewer side effects, yet the field continues to show few successes. Nevertheless, fast-advancing knowledge, a huge market, and better clinical study de-risking strategies should eventually overcome investor shyness about backing emerging personalized pain drug developers.